Pre-and Postgraduate Training in Molecular Hematology

分子血液学预科和研究生培训

基本信息

  • 批准号:
    10413815
  • 负责人:
  • 金额:
    $ 52.19万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    1975
  • 资助国家:
    美国
  • 起止时间:
    1975-07-01 至 2026-06-30
  • 项目状态:
    未结题

项目摘要

Although advances in hematology have led the way in many fields of basic and translational biomedical research, hematologic diseases remain major threats to public health. For example, the prognosis for many hematologic malignancies continues to be poor. Current treatments are inadequate to support a normal lifestyle for most patients with sickle cell disease. In the U.S., at least 500,000 venous thromboembolic events, 1 million heart attacks and 150,000 stroke deaths occur each year. At the same time, opportunities for hematology research have never been more promising, and converting these opportunities into medical advances will depend upon training the next generation of basic and translational hematology researchers. The Molecular Hematology train- ing program proposes to fill this need for 5 predoctoral and 8 postdoctoral trainees per year. Predoctoral Ph.D. and M.D./Ph.D. students follow the curriculum of the Washington University graduate school. After passing their qualifying examination, they enter the laboratory of participating faculty Mentors for 3-4 years of laboratory re-search to complete their dissertation. Postdoctoral Ph.D. trainees from around the world apply to participating laboratories; postdoctoral M.D. and M.D./Ph.D. trainees usually have completed the clinical training component of a Hematology-Oncology fellowship program at Washington University or elsewhere. The duration of postdoc-toral training depends on prior experience. Those with Ph.D. or M.D./Ph.D degrees typically conduct research for 2-3 years before transitioning to an independent research position, whereas those with an M.D. degree may benefit from 3-4 years of postdoctoral training. Trainees receive intensive mentoring and career counseling, and participate in coursework, journal clubs, and seminars. The major facilities of the program consist of ~80,000 square feet of fully-equipped laboratory space that house the Divisions of Hematology and Oncology, as well as extensive institutional resources for genome sequencing, immune monitoring, informatics, animal studies, and patient-oriented clinical research. The research topics available to trainees reflect the multidisciplinary expertise of the participating Mentors and include: pathogenesis of hemorrhagic and thrombotic disorders; regulation of blood coagulation and fibrinolysis; gene therapy of hemophilia and lysosomal storage diseases; phosphoinosi-tide metabolism and cell signaling pathways; mechanisms of hematopoiesis; telomerase defects in bone marrow failure syndromes; molecular basis for protein trafficking in mammalian cells; role of platelets and angiogenesis in metastasis; biology of human immunodeficiency and leukemia viruses; epithelial morphogenesis; pathogene-sis of leukemia, myelodysplastic syndrome, myeloproliferative neoplasms, and congenital neutropenia; cell cycle control; programmed cell death in development and malignancy. Completion of this program will prepare talented trainees for careers in basic and translational hematology research, to make discoveries that will transform the diagnosis and treatment of hematologic diseases.
尽管血液学的进步引领了基础和转化生物医学研究的许多领域, 血液疾病仍然是公众健康的主要威胁。例如,许多血液学疾病的预后 恶性肿瘤的发病率仍然很低。目前的治疗不足以支持大多数人的正常生活方式 镰状细胞病患者。在美国,至少有 50 万起静脉血栓栓塞事件、100 万起心脏事故 每年都会发生 15 万人中风死亡。同时,血液学研究的机会 从未如此有希望,将这些机会转化为医学进步将取决于 培训下一代基础和转化血液学研究人员。分子血液学培训- ing 计划建议每年满足 5 名博士前培训生和 8 名博士后培训生的需求。博士前 博士和医学博士/博士学生遵循华盛顿大学研究生院的课程。后 通过资格考试后,他们将进入参与教师导师的实验室进行3-4年的学习 实验室研究以完成论文。博士后 博士来自世界各地的学员申请 参与实验室;博士后医学博士和医学博士/博士受训者通常已经完成了临床 华盛顿大学或其他地方的血液学-肿瘤学奖学金计划的培训组成部分。这 博士后培训的持续时间取决于先前的经验。那些拥有博士学位的人。或医学博士/博士学位 通常在过渡到独立研究职位之前进行 2-3 年的研究,而 拥有医学博士学位的人可能会受益于3-4年的博士后培训。学员接受强化培训 指导和职业咨询,并参加课程、期刊俱乐部和研讨会。主要 该项目的设施包括约 80,000 平方英尺的设备齐全的实验室空间,其中容纳了 血液学和肿瘤学部门以及用于基因组测序的广泛机构资源, 免疫监测、信息学、动物研究和以患者为导向的临床研究。研究课题 学员可以获得的内容反映了参与导师的多学科专业知识,包括: 出血性和血栓性疾病的发病机制;调节血液凝固和纤维蛋白溶解;基因 血友病和溶酶体贮积病的治疗;磷酸肌醇代谢和细胞信号传导 途径;造血机制;骨髓衰竭综合征中的端粒酶缺陷;分子 哺乳动物细胞中蛋白质运输的基础;血小板和血管生成在转移中的作用;的生物学 人类免疫缺陷和白血病病毒;上皮形态发生;白血病的发病机制, 骨髓增生异常综合征、骨髓增生性肿瘤和先天性中性粒细胞减少症;细胞周期控制; 发育和恶性肿瘤中的程序性细胞死亡。完成该计划将为有才华的人做好准备 基础和转化血液学研究职业的受训者,做出将改变血液学研究的发现 血液系统疾病的诊断和治疗。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Stephen Tracy Oh其他文献

Stephen Tracy Oh的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Stephen Tracy Oh', 18)}}的其他基金

DYSREGULATED NFKB PATHWAY SIGNALING IN MYELOPROLIFERATIVE NEOPLASMS
骨髓增生性肿瘤中 NFKB 通路信号传导失调
  • 批准号:
    9448313
  • 财政年份:
    2017
  • 资助金额:
    $ 52.19万
  • 项目类别:
DYSREGULATED NFKB PATHWAY SIGNALING IN MYELOPROLIFERATIVE NEOPLASMS
骨髓增生性肿瘤中 NFKB 通路信号传导失调
  • 批准号:
    10321938
  • 财政年份:
    2017
  • 资助金额:
    $ 52.19万
  • 项目类别:
ACQUISITION OF A SINGLE CELL MASS CYTOMETER (CYTOF)
购买单细胞质谱仪 (CYTOF)
  • 批准号:
    8640344
  • 财政年份:
    2014
  • 资助金额:
    $ 52.19万
  • 项目类别:
ABERRANT JAK-STAT SIGNALING DUE TO LNK MUTATIONS IN MYELOPROLIFERATIVE NEOPLASMS
骨髓增生性肿瘤中 LNK 突变导致 JAK-STAT 信号异常
  • 批准号:
    8686926
  • 财政年份:
    2012
  • 资助金额:
    $ 52.19万
  • 项目类别:
ABERRANT JAK-STAT SIGNALING DUE TO LNK MUTATIONS IN MYELOPROLIFERATIVE NEOPLASMS
骨髓增生性肿瘤中 LNK 突变导致 JAK-STAT 信号异常
  • 批准号:
    9088503
  • 财政年份:
    2012
  • 资助金额:
    $ 52.19万
  • 项目类别:
ABERRANT JAK-STAT SIGNALING DUE TO LNK MUTATIONS IN MYELOPROLIFERATIVE NEOPLASMS
骨髓增生性肿瘤中 LNK 突变导致 JAK-STAT 信号异常
  • 批准号:
    8299207
  • 财政年份:
    2012
  • 资助金额:
    $ 52.19万
  • 项目类别:
ABERRANT JAK-STAT SIGNALING DUE TO LNK MUTATIONS IN MYELOPROLIFERATIVE NEOPLASMS
骨髓增生性肿瘤中 LNK 突变导致 JAK-STAT 信号异常
  • 批准号:
    8448195
  • 财政年份:
    2012
  • 资助金额:
    $ 52.19万
  • 项目类别:
ABERRANT JAK-STAT SIGNALING DUE TO LNK MUTATIONS IN MYELOPROLIFERATIVE NEOPLASMS
骨髓增生性肿瘤中 LNK 突变导致 JAK-STAT 信号异常
  • 批准号:
    8882524
  • 财政年份:
    2012
  • 资助金额:
    $ 52.19万
  • 项目类别:
PRE-AND POSTGRADUATE TRAINING IN MOLECULAR HEMATOLOGY
分子血液学学前和研究生培训
  • 批准号:
    9918435
  • 财政年份:
    1975
  • 资助金额:
    $ 52.19万
  • 项目类别:
Pre-and Postgraduate Training in Molecular Hematology
分子血液学预科和研究生培训
  • 批准号:
    10676759
  • 财政年份:
    1975
  • 资助金额:
    $ 52.19万
  • 项目类别:

相似海外基金

Prognostic implications of mitochondrial inheritance in myelodysplastic syndromes after stem-cell transplantation
干细胞移植后骨髓增生异常综合征线粒体遗传的预后意义
  • 批准号:
    10662946
  • 财政年份:
    2023
  • 资助金额:
    $ 52.19万
  • 项目类别:
Anticoagulant use, safety, and effectiveness for venous thromboembolism prevention in inflammatory bowel disease patients
炎症性肠病患者预防静脉血栓栓塞的抗凝剂使用、安全性和有效性
  • 批准号:
    10887842
  • 财政年份:
    2023
  • 资助金额:
    $ 52.19万
  • 项目类别:
Elucidating the role of DCAF7 on hematopoietic stem cell maintenance
阐明 DCAF7 对造血干细胞维持的作用
  • 批准号:
    10785443
  • 财政年份:
    2023
  • 资助金额:
    $ 52.19万
  • 项目类别:
Understand Non-canonical RAS Signaling in Clonal Hematopoietic Disorders
了解克隆性造血疾病中的非典型 RAS 信号转导
  • 批准号:
    10571352
  • 财政年份:
    2023
  • 资助金额:
    $ 52.19万
  • 项目类别:
Applied Systems Biology Core
应用系统生物学核心
  • 批准号:
    10746901
  • 财政年份:
    2023
  • 资助金额:
    $ 52.19万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了